Bone3Dmatch revolutionizes the market of bone grafting with a new generation of synthetic biomaterials. The solution is synthetic, biomimetic and patient-specific, offering shaking disruptions in bone grafting, whether in the concept or in the performance.
It is vital to mention that the world performs over 2 million bone grafting procedures annually worldwide. Most important, nearly half of them take place in the European Union. And this makes bone grafts the second most transplanted tissue after blood
Traditional Bone Grafting Limitations
Inevitably, bone defects pose a tremendous clinical and socio-economic problem, only worsening with the aging population. Despite that bone harvested from the patient, bone banks, or animals are common standards, those present serious disadvantages. To enumerate, limited availability, immune responses, disease transmission, and ethical issues figure in the top ten limitations. Later, various companies developed synthetic bone grafts to minimize complications. Still, they are, to this day, faced with low success and failing to accelerate natural bone growth.
How does Bone3DMatch Disrupt Bone Grafting?
Having this in mind, Bone3Dmatch revolutionizes the market of bone grafting (3.2bn€ globally) with a new generation of synthetic biomaterials.
This solution brings forward two main disruptions:
- First, Biomimicry: The biomaterial, thanks to its aqueous composition, and low-temperature processing, is capable of mimicking the bone creation conditions. Thus, it is recognized as natural bone by bone cells, accelerating the bone regeneration and the patient’s recovery.
- Second, Patient Customization: Through advanced 3D printing technologies, it manufactures patient-specific scaffolds in less than 72h. So this latter enables the treatment of complex bone defects, changing the current paradigm to a patient-specific treatment.
Who Is Behind Bone3DMatch?
The company behind Bone3Dmatch is Mimetis; a young SME built on the back of 25 years of research and business acumen in biomaterials for bone regeneration. Currently, Mimetis offers biomimetic granules for the dental market. And with an investment of 1.1M€, Bone3Dmatch will undoubtedly accelerate the market introduction of the fourth generation biomaterial in an entirely new form (3D-printed scaffolds). Mainly, Mimetis will target orthopedics and craniomaxillofacial disciplines. In the long run, we expect to reach the market in 2020, achieving 4,9M€ in revenues in only three years. Moreover, our ambition is to deploy a decentralized model where hospitals around the world can print their own patient-specific implants using our biomimetic biomaterial.